Literature DB >> 10389638

Toward a canine model of atopic dermatitis: amplification of cytokine-gene transcripts in the skin of atopic dogs.

T Olivry1, G A Dean, M B Tompkins, J L Dow, P F Moore.   

Abstract

The objectives of the present study were to characterize and compare the repertoire of cytokine-genes transcribed in skin homogenates obtained from normal dogs and dogs with atopic dermatitis (AD) using a reverse-transcriptase polymerase chain reaction and canine-specific cytokine-gene primers. Whereas IL-4 and IL-5 cytokine-gene transcripts were detected more commonly in atopic skin biopsy homogenates, IL-2 mRNA was amplified more often from normal control specimens. IFN-gamma mRNA was detected in 5/29 atopic specimens, 4 of them obtained from the only dog with chronic skin lesions. One-fourth of atopic samples exhibited clear type-2 cytokine profiles; the remainder did not demonstrate polarized repertoires. Conversely, type-1 cytokine profiles were characterized in one-fourth of normal control specimens. The present study establishes, for the first time, the transcription of type-2 cytokine-genes in the skin of dogs with AD. Future experiments investigating the cellular origin and dynamics of allergic cytokine-gene transcription are needed to confirm whether or not canine AD could be considered an immunological model for a human disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389638     DOI: 10.1111/j.1600-0625.1999.tb00372.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  11 in total

1.  A canine model of cutaneous late-phase reactions: prednisolone inhibition of cellular and cytokine responses.

Authors:  Cherie M Pucheu-Haston; Dale Shuster; Thierry Olivry; Philippe Brianceau; Patrick Lockwood; Terrill McClanahan; Rene de Waal Malefyt; Jeanine D Mattson; Bruce Hammerberg
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

2.  Current Knowledge on Canine Atopic Dermatitis: Pathogenesis and Treatment.

Authors:  Catherine A Outerbridge; Tyler J M Jordan
Journal:  Adv Small Anim Care       Date:  2021-09-29

3.  Quantification of indoleamine 2,3-dioxygenase gene induction in atopic and non-atopic monocytes after ligation of the high-affinity receptor for IgE, Fc(epsilon)RI and interferon-gamma stimulation.

Authors:  D von Bubnoff; G Bezold; H Matz; D Hanau; H De La Salle; T Bieber
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

4.  Intradermal injection of Hsp60 induces cytokine responses in canine atopic and healthy skin.

Authors:  Annette Jassies-van der Lee; Victor Rutten; Peter van Kooten; Ruurd van der Zee; Ton Willemse
Journal:  Cell Stress Chaperones       Date:  2008-03-13       Impact factor: 3.667

5.  Inhibitory effects of interleukin-10 plasmid DNA on the development of atopic dermatitis-like skin lesions in NC/Nga mice.

Authors:  Bock Gie Jung; Sun Ju Cho; Jae Hyung Ko; Bong Joo Lee
Journal:  J Vet Sci       Date:  2010-09       Impact factor: 1.672

6.  Altered plasma cytokines in dogs with atopic dermatitis.

Authors:  Hamutal Mazrier; Linda J Vogelnest; Rosanne M Taylor; Peter Williamson
Journal:  Vet Dermatol       Date:  2021-11-24       Impact factor: 1.867

7.  A study on periostin involvement in the pathophysiology of canine atopic skin.

Authors:  Takayuki Mineshige; Junichi Kamiie; Go Sugahara; Kinji Shirota
Journal:  J Vet Med Sci       Date:  2017-11-27       Impact factor: 1.267

8.  Transcriptomes from German shepherd dogs reveal differences in immune activity between atopic dermatitis affected and control skin.

Authors:  K Tengvall; K Bergvall; M Olsson; B Ardesjö-Lundgren; F H G Farias; M Kierczak; Å Hedhammar; K Lindblad-Toh; G Andersson
Journal:  Immunogenetics       Date:  2020-06-18       Impact factor: 2.846

Review 9.  Atopic dermatitis in cats and dogs: a difficult disease for animals and owners.

Authors:  Natalie Katharina Yvonne Gedon; Ralf Steffen Mueller
Journal:  Clin Transl Allergy       Date:  2018-10-05       Impact factor: 5.871

10.  Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.

Authors:  A J Gonzales; J W Bowman; G J Fici; M Zhang; D W Mann; M Mitton-Fry
Journal:  J Vet Pharmacol Ther       Date:  2014-02-05       Impact factor: 1.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.